CompletedNot Applicable

MyoStrain CMR for the Detection of Cardiotoxicity

Germany63 participantsStarted 2017-08-01

Plain-language summary

The Prefect Pilot Study evaluates the use of the EC approved MyoStrain SENC CMR Imaging System to detect cardiotoxicity from drugs used to treat cancer (e.g. Breast Cancer and Lymphomas).

Who can participate

Age range18 Years – 80 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Undergoing Chemotherapy for Cancer Treatment * Provided Written Informed Consent Exclusion Criteria: * Contraindication to Magnetic Resonance Imaging * Pregnancy

What they're measuring

Accuracy of MyoStrain to Detect Cardiotoxicity

Timeframe: 6 months

Trial details

NCT IDNCT03543228

SponsorMyocardial Solutions

Sponsor typeINDUSTRY

Study typeOBSERVATIONAL

Primary completion2020-01-31

View on ClinicalTrials.gov More Cardiotoxicity trials